pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
IONIS PHARMACEUTICALS INC ($IONS) · news · pharmadog
← back to IONIS PHARMACEUTICALS INC
News mentioning $IONS
68
stories
2d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
3d
Lawmakers hear mixed opinions on psychedelics credentialing
endpoints
10d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
10d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
11d
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
11d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
11d
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
11d
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
12d
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
fiercebiotech
20d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
23d
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
25d
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
biospace
26d
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
biospace
26d
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
26d
Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
biospace
29d
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
biopharma dive
Sep 4, 26
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
fiercebiotech
Sep 4, 26
Ionis wins FDA approval of Alexander disease drug zilganersen
endpoints
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 4, 26
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
fiercebiotech
Sep 3, 26
FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
biospace
Sep 3, 26
STAT+: Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder
stat
Sep 3, 26
FDA Approves First Drug to Treat Alexander Disease
fda press
Sep 3, 26
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
biopharma dive
Aug 31, 26
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
Aug 31, 26
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
fiercebiotech
Aug 31, 26
Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
biospace
Aug 30, 26
#ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closer
endpoints
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
biopharma dive
← prev
page 1 of 3
next →
